Last reviewed · How we verify
L606
L606 is an inhaled dry powder formulation of treprostinil designed to deliver the prostacyclin analog directly to the lungs for pulmonary hypertension treatment.
L606 is an inhaled dry powder formulation of treprostinil designed to deliver the prostacyclin analog directly to the lungs for pulmonary hypertension treatment. Used for Pulmonary arterial hypertension (PAH).
At a glance
| Generic name | L606 |
|---|---|
| Also known as | Treprostinil Liposome Inhalation Suspension |
| Sponsor | Liquidia Technologies, Inc. |
| Drug class | Prostacyclin analog |
| Target | Prostacyclin receptor (IP receptor) |
| Modality | Small molecule |
| Therapeutic area | Pulmonary Hypertension |
| Phase | Phase 3 |
Mechanism of action
L606 uses Liquidia's PRINT technology to create uniform, engineered particles of treprostinil that can be inhaled as a dry powder. Treprostinil is a prostacyclin analog that acts as a vasodilator and antiplatelet agent, reducing pulmonary vascular resistance and improving hemodynamics in pulmonary hypertension patients. The dry powder inhalation route provides direct lung delivery with potentially improved bioavailability and patient convenience compared to parenteral formulations.
Approved indications
- Pulmonary arterial hypertension (PAH)
Common side effects
- Cough
- Headache
- Throat irritation
- Flushing
Key clinical trials
- A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD (PHASE3)
- A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD (PHASE3)
- Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |